The Day -- Two analyses of Pfizer Inc.'s failed drug torcetrapib have concluded that similar compounds boosting good cholesterol might have a chance of succeeding - if they can avoid negative side effects.
The Day -- Two analyses of Pfizer Inc.'s failed drug torcetrapib have concluded that similar compounds boosting good cholesterol might have a chance of succeeding - if they can avoid negative side effects.
